Perrigo (PRGO) vs UroGen Pharma (URGN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
UroGen Pharma (URGN) has outperformed Perrigo (PRGO) over the past year, gaining 113.4% versus a loss of 32.9%. Over five years, URGN leads with a +117.3% price change compared with -67.5% for PRGO. Perrigo is the larger company by market cap ($2.01 billion vs $1.81 billion), about 1.1 times the size.
On valuation, Perrigo trades at a lower forward P/E (6.0x vs 13.2x for UroGen Pharma). Perrigo pays a dividend yielding 8.00%, while UroGen Pharma does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PRGO | URGN |
|---|---|---|
| Share price | $14.50 | $36.98 |
| Market cap | $2.01B | $1.81B |
| 1-day change | -0.34% | -9.14% |
| YTD return | +4.53% | +57.90% |
| 1-year return | -32.89% | +113.39% |
| 5-year return | -67.46% | +117.27% |
| Forward P/E | 6.05 | 13.23 |
| EPS (TTM) | $-12.28 | $-1.97 |
| Dividend yield | 8.00% | 0.00% |
| Annual dividend | $1.16 | $0.00 |
| 52-week high | $22.02 | $50.81 |
| 52-week low | $9.23 | $15.86 |
| Distance from 52-week high | -34.15% | -27.22% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +13.79% | +62.25% |
| Average volume | 2.80M | 849.01K |
| Shares outstanding | 138.37M | 48.88M |
| Employees | 8,100 | 300 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- URGN has outperformed PRGO by 146.3 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (8.00% vs 0.00%).
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
About UroGen Pharma
URGN stock →UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions.
Health Care · Biotechnology: Pharmaceutical Preparations · 300 employees
PRGO vs URGN FAQ
Which is bigger, Perrigo or UroGen Pharma?
Perrigo (PRGO) is larger, with a market capitalization of $2.01B compared with $1.81B for UroGen Pharma (URGN).
Which stock has performed better over the past year, PRGO or URGN?
URGN returned +113.39% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Perrigo or UroGen Pharma?
Perrigo pays a dividend yielding 8.00%, while UroGen Pharma does not currently pay a regular dividend.
Are Perrigo and UroGen Pharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.